Cardiovascular Translational Medicine Director

Merck & Co.; Rahway (NJ); Hybrid; USD 260,000 - 410,000; Full time

Job summary

Merck & Co. seeks a Principal Scientist (Clinical Director) to lead early clinical development programs and biomarker strategies across cardiovascular and related diseases.

The role collaborates with Discovery Sciences and late-stage Clinical Research to translate preclinical findings into human studies. The candidate will guide clinical pharmacology strategies, design biomarker platforms, and coordinate global studies through Phase 2/4, while communicating results to governance committees and

Qualifications

• Proven track record in clinical medicine or clinical research.
• Publication record or presentations demonstrates scientific scholarship.
• Willingness to work collaboratively across different therapeutic areas.
• Strong interpersonal, writing and presentation skills are essential.

Responsibilities

• Lead early clinical development strategy within Translational Medicine.
• Author clinical and biomarker plans for Lead Optimization and early development programs.
• Design and execute studies to validate clinical platforms using biomarkers and imaging.
• Provide clinical pharmacology support from Phase I to worldwide regulatory submissions.
• Communicate study results clearly to governance bodies and cross-functional teams.
• Collaborate with Discovery Sciences, Preclinical Pharmacology, and Clinical Research teams globally.

Skills

Clinical research leadership

Publications track record

Cross-functional collaboration

Education

MD or MD/PhD

Job description

Merck & Co. seeks a Principal Scientist (Clinical Director) to lead early clinical development programs and biomarker strategies across cardiovascular and related diseases.

The role collaborates with Discovery Sciences and late-stage Clinical Research to translate preclinical findings into human studies. The candidate will guide clinical pharmacology strategies, design biomarker platforms, and coordinate global studies through Phase 2/4, while communicating results to governance committees and